A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Protocol YY-20394-007 is a phase1 open-label, single-arm, multi-centre study to assess the
safety and efficacy of YY-20394 in participants with relapse and/or refractory B cell
malignant hematological tumor. eligible participants will initiate oral therapy with YY-20394
at a starting dose of 80mg taken once per day. treatment with YY-20394 can continue in
compliant participants as long as the study is still ongoing and the participants appear to
benefiting from treatment with acceptable safety.